Matching articles for "Antimicrobials"
Issue 125 · January 1, 2013
Drugs for Acne, Rosacea and Psoriasis

The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium…

Treat Guidel Med Lett. 2013 Jan; 11(125):1-8
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Issue 1323 · October 19, 2009
Generic Drugs Revisited

The equivalence of generic drugs to their brand-name precursors continues to be controversial. The last Medical Letter review of this subject (2002) concluded that well-documented therapeutic inequivalence…

Med Lett Drugs Ther. 2009 Oct 19; 51(1323):81-2
The equivalence of generic drugs to their brand-name precursors continues to be controversial. The last Medical Letter review of this subject (2002) concluded that well-documented therapeutic inequivalence between brand-name and FDA-approved generic drugs had not been reported. Is that still true? New data have become available for some drugs.
Issue 1310 · April 20, 2009
Adapalene-Benzoyl Peroxide (Epiduo) for Acne

Epiduo gel (Galderma), a fixed-dose combination of adapalene 0.1% (Differin) , a synthetic retinoid analog, and benzoyl peroxide (BPO) 2.5%, an oxidizing agent, has been approved by the FDA for topical…

Med Lett Drugs Ther. 2009 Apr 20; 51(1310):31-2
Epiduo gel (Galderma), a fixed-dose combination of adapalene 0.1% (Differin) , a synthetic retinoid analog, and benzoyl peroxide (BPO) 2.5%, an oxidizing agent, has been approved by the FDA for topical treatment of acne vulgaris in patients ≥12 years old.
Issue 57 · May 1, 2007
Choice of Antibacterial Drugs

Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric…

Treat Guidel Med Lett. 2007 May; 5(57):33-50
Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric treatment for some common types of infections are summarized in the text and a table listing the drugs of choice and alternatives for each pathogen begins on page 40. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 52 · December 1, 2006
Antimicrobial Prophylaxis for Surgery

Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain procedures. Recommendations for prevention of surgical site infection are listed in this…

Treat Guidel Med Lett. 2006 Dec; 4(52):83-8
Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain procedures. Recommendations for prevention of surgical site infection are listed in this article.
Issue 1247 · November 6, 2006
Treatment of Clostridium difficile-Associated Disease (CDAD)

The gram-positive anaerobic bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea. The antibiotics most often implicated have been ampicillin, second and third…

Med Lett Drugs Ther. 2006 Nov 6; 48(1247):89-90
The gram-positive anaerobic bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea. The antibiotics most often implicated have been ampicillin, second and third generation cephalosporins, clindamycin and fluoroquinolones. The emergence in recent years of a new, more toxic epidemic strain (BI/NAP1), possibly related to widespread use of fluoroquinolones, has caused a marked increase in the incidence and severity of C. difficile -associated disease (CDAD).
Issue 1233 · April 24, 2006 Free
In Brief: Telithromycin Hepatotoxicity

Telithromycin (Ketek) is an oral erythromycin derivative FDA-approved for treatment of mild to moderate community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial sinusitis (Med Lett…

Med Lett Drugs Ther. 2006 Apr 24; 48(1233):33
Telithromycin (Ketek) is an oral erythromycin derivative FDA-approved for treatment of mild to moderate community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial sinusitis (Med Lett Drugs Ther 2004; 46:66) . It is generally considered an alternative antibiotic because of its cost, potential for adverse effects including visual disturbances, exacerbation of myasthenia gravis, hepatotoxicity and drug interactions. A recent report (Ann Intern Med 2006; 144:415) described serious hepatotoxicity probably related to telithromycin in three patients, including one who died and another who needed a liver transplant. Many other oral antibiotics are available for treatment of community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial sinusitis in adults (Med Lett Drugs Ther 2005; 47:78) .
Issue 1218 · September 28, 2005
Azithromycin Extended-Release (Zmax) for Sinusitis and Pneumonia

Zmax (Pfizer), an extended-release oral suspension of azithromycin, has been approved by the FDA for single dose treatment of mild to moderate community acquired pneumonia (CAP) and acute bacterial sinusitis…

Med Lett Drugs Ther. 2005 Sep 28; 47(1218):78-80
Zmax (Pfizer), an extended-release oral suspension of azithromycin, has been approved by the FDA for single dose treatment of mild to moderate community acquired pneumonia (CAP) and acute bacterial sinusitis (ABS) in adults. Immediate-release azithromycin will probably become available generically later this year when its patent expires.
Issue 1217 · September 12, 2005
Tigecycline (Tygacil)

Tigecycline ( Tygacil - Wyeth), a derivative of minocycline, is a new intravenous (IV) antibiotic approved for treatment of complicated intra-abdominal and skin and skin-structure infections.

Med Lett Drugs Ther. 2005 Sep 12; 47(1217):73-4
Tigecycline ( Tygacil - Wyeth), a derivative of minocycline, is a new intravenous (IV) antibiotic approved for treatment of complicated intra-abdominal and skin and skin-structure infections.
Issue 1192 · September 20, 2004
Gemifloxacin (Factive)

Gemifloxacin ( Factive - Oscient), a new oral fluoroquinolone antibiotic, has been approved by the FDA for 5 days' treatment of acute bacterial exacerbations of chronic bronchitis (ABECB) and 7 days' treatment…

Med Lett Drugs Ther. 2004 Sep 20; 46(1192):78-9
Gemifloxacin ( Factive - Oscient), a new oral fluoroquinolone antibiotic, has been approved by the FDA for 5 days' treatment of acute bacterial exacerbations of chronic bronchitis (ABECB) and 7 days' treatment of mild to moderate community-acquired pneumonia (CAP) in adults. For the next 6-8 months it will only be available, presumably for commercial reasons, in states east of the Rocky Mountains.
Issue 1189 · August 16, 2004
Telithromycin (Ketek) for Respiratory Infections

Telithromycin ( Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in…

Med Lett Drugs Ther. 2004 Aug 16; 46(1189):66-8
Telithromycin ( Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in patients age 18 and older. The drug is the first in a new class of antibiotics, the ketolides, derived from the macrolide erythromycin. Telithromycin has been marketed in Europe since 2001.
Issue 20 · April 1, 2004
Antimicrobial Prophylaxis for Surgery

Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain operations, but this benefit must be weighed against the risks of toxic and allergic…

Treat Guidel Med Lett. 2004 Apr; 2(20):27-32
Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain operations, but this benefit must be weighed against the risks of toxic and allergic reactions, emergence of resistant bacteria, adverse drug interactions, superinfection and cost. Medical Letter consultants generally recommend antimicrobial prophylaxis only for procedures with high infection rates, those involving implantation of prosthetic material, and those in which the consequences of infection are likely to be especially serious.
Issue 19 · March 1, 2004
Choice of Antibacterial Drugs

New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the…

Treat Guidel Med Lett. 2004 Mar; 2(19):13-22
New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the drugs of choice and alternatives for each pathogen begins on page 18. These recommendations are based on results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants. Local resistance patterns should be taken into account. Trade names are listed on page 24.
Issue 884 · November 27, 1992
Cefpodoxime Proxetil - A New Oral Cephalosporin

Cefpodoxime proxetil ( Vantin - Upjohn), a new third-generation oral cephalosporin, has been approved for marketing by the US Food and Drug Administration. It is available for twice-daily treatment of…

Med Lett Drugs Ther. 1992 Nov 27; 34(884):107-8
Cefpodoxime proxetil ( Vantin - Upjohn), a new third-generation oral cephalosporin, has been approved for marketing by the US Food and Drug Administration. It is available for twice-daily treatment of pharyngitis, upper and lower respiratory infections, otitis media, urinary tract infections, skin and soft tissue infections, and for single-dose treatment of uncomplicated gonorrhea in men or women and anorectal gonorrhea in women.
Issue 883 · November 13, 1992
Enoxacin - A New Fluoroquinolone

Enoxacin (en ox' a sin; Penetrex - Rh ne-Poulenc Rorer), a fluoroquinolone antimicrobial for oral use, has now been marketed in the USA for treatment of urinary tract infections and uncomplicated urethral or…

Med Lett Drugs Ther. 1992 Nov 13; 34(883):103-5
Enoxacin (en ox' a sin; Penetrex - Rh ne-Poulenc Rorer), a fluoroquinolone antimicrobial for oral use, has now been marketed in the USA for treatment of urinary tract infections and uncomplicated urethral or cervical gonorrhea.
Issue 879 · September 18, 1992
Loracarbef

Loracarbef ( Lorabid - Lilly), a new beta-lactam antibiotic with antimicrobial activity similar to the second-generation cephalosporins, has been approved by the US Food and Drug Administration for treatment…

Med Lett Drugs Ther. 1992 Sep 18; 34(879):87-8
Loracarbef ( Lorabid - Lilly), a new beta-lactam antibiotic with antimicrobial activity similar to the second-generation cephalosporins, has been approved by the US Food and Drug Administration for treatment of respiratory, skin, and urinary tract infection caused by susceptible organisms in both adults and children. It will probably compete with drugs such as trimethoprim-sulfamethoxazole ( Bactrim , Septra , and others), amoxicillin-clavulanic acid ( Augmentin ), cefaclor ( Ceclor ), cefuroxime axetil ( Ceftin ), and cefprozil ( Cefzil - Medical Letter, 34:63, 1992).
Issue 873 · June 26, 1992
Cefprozil

Cefprozil ( Cefzil - Bristol-Myers Squibb), a new oral second-generation cephalosporin, was recently released in the USA for treatment of pharyngitis, bronchitis, otitis media, and skin and skin-structure…

Med Lett Drugs Ther. 1992 Jun 26; 34(873):63-4
Cefprozil ( Cefzil - Bristol-Myers Squibb), a new oral second-generation cephalosporin, was recently released in the USA for treatment of pharyngitis, bronchitis, otitis media, and skin and skin-structure infections.
Issue 872 · June 12, 1992
Two New Fluoroquinolones

Temafloxacin ( Omniflox - Abbott) and lomefloxacin ( Maxaquin - Searle) are the latest fluoroquinolone antimicrobial agents to be approved by the US Food and Drug Administration (FDA) for oral treatment of…

Med Lett Drugs Ther. 1992 Jun 12; 34(872):58-60
Temafloxacin ( Omniflox - Abbott) and lomefloxacin ( Maxaquin - Searle) are the latest fluoroquinolone antimicrobial agents to be approved by the US Food and Drug Administration (FDA) for oral treatment of various infections. Previously marketed include norfloxacin ( Noroxin - Medical Letter, 29:25, 1987), ciprofloxacin ( Cipro - Medical Letter, 30:11, 1988), and ofloxacin ( Floxin - Medical Letter, 33:71, 1991). Norfloxacin is marketed only for treatment of urinary tract infections, and lomefloxacin only for treatment of urinary tract infections and bronchitis known to be caused by Haemophilus influenzae or Moraxella catarrhalis . Ciprofloxacin and ofloxacin are also available in parenteral formulations.
Issue 871 · May 29, 1992
The Choice Antibacterial Drugs

Since The Medical Letter last reviewed antibacterial drugs (vol.32, page 41, 1990), a few new drugs have become available, and some clinical trials of older drugs have been published. The drug of choice for…

Med Lett Drugs Ther. 1992 May 29; 34(871):49-56
Since The Medical Letter last reviewed antibacterial drugs (vol.32, page 41, 1990), a few new drugs have become available, and some clinical trials of older drugs have been published. The drug of choice for treatment of an infection is usually the most active drug against the pathogenic organism or the least toxic alternative among several effective agents. Sometimes the choice of drugs is modified by the site of infection; one drug may penetrate better than another, for example, into bile, urine, or cerebrospinal fluid. The patient's clinical status may also influence the choice as, for example, when a patient has diminished renal or hepatic function, or is immunocompromised, pregnant, or allergic to penicillin. Finally, when other factors are about equal, the relative cost of the drug may be a consideration.
Issue 870 · May 15, 1992
Clarithromycin and Azithromycin

Clarithromycin ( Biaxin - Abbott) and azithromycin ( Zithromax - Pfizer), two macrolide antibiotics chemically related to erythromycin, have been approved by the US Food and Drug Administration for treatment…

Med Lett Drugs Ther. 1992 May 15; 34(870):45-7
Clarithromycin ( Biaxin - Abbott) and azithromycin ( Zithromax - Pfizer), two macrolide antibiotics chemically related to erythromycin, have been approved by the US Food and Drug Administration for treatment of respiratory, skin, and skin structure infections. Azithromycin has also been approved for treatment of nongonococcal urethritis and cervicitis caused by Chlamydia trachomatis .
Issue 850 · August 9, 1991
Intravenous Ciprofloxacin

Ciprofloxacin, previously available orally ( Cipro - Medical Letter, 30:11, 1988) and for ophthalmic use ( Ciloxan - Medical Letter, 33:52, May 31, 1991), is now the first fluoroquinolone antibiotic to become…

Med Lett Drugs Ther. 1991 Aug 9; 33(850):75-6
Ciprofloxacin, previously available orally ( Cipro - Medical Letter, 30:11, 1988) and for ophthalmic use ( Ciloxan - Medical Letter, 33:52, May 31, 1991), is now the first fluoroquinolone antibiotic to become available in the USA in an intravenous (IV) formulation. Cipro I.V. (Miles) is being promoted as an alternative to third-generation cephalosporins, aminoglycosides, and other drugs used for treatment of serious infections.
Issue 849 · July 26, 1991
Ofloxacin

Ofloxacin ( Floxin - McNeil, Ortho), a new fluoroquinolone antibacterial agent, was recently marketed in the USA for oral treatment of various infections caused by susceptible microorganisms. Ofloxacin is the…

Med Lett Drugs Ther. 1991 Jul 26; 33(849):71-3
Ofloxacin ( Floxin - McNeil, Ortho), a new fluoroquinolone antibacterial agent, was recently marketed in the USA for oral treatment of various infections caused by susceptible microorganisms. Ofloxacin is the third fluoroquinolone to become available in this country. Norfloxacin ( Noroxin - Medical Letter, 29:25, 1987) is marketed only for treatment of urinary tract infections. Ciprofloxacin ( Cipro - Medical Letter, 30:11, 1988), like ofloxacin, is approved for use in a variety of infections.
Issue 845 · May 31, 1991
Ophthalmic Ciprofloxacin

An ophthalmic formulation of ciprofloxacin hydrochloride ( Ciloxan - Alcon), a fluoroquinolone antibiotic, was recently marketed in the USA for treatment of bacterial keratitis and conjunctivitis.…

Med Lett Drugs Ther. 1991 May 31; 33(845):52-3
An ophthalmic formulation of ciprofloxacin hydrochloride ( Ciloxan - Alcon), a fluoroquinolone antibiotic, was recently marketed in the USA for treatment of bacterial keratitis and conjunctivitis. Ciprofloxacin has been used orally ( Cipro ) to treat a variety of serious infections (Medical Letter, 30:11, 1988) and recently was approved for intravenous administration.
Issue 832 · November 30, 1990
Choice of Cephalosporin

Since the last Medical Letter review of cephalosporin antibiotics (volume 25, page 57, 1983), many new cephalosporins have become available in the USA.

Med Lett Drugs Ther. 1990 Nov 30; 32(832):107-10
Since the last Medical Letter review of cephalosporin antibiotics (volume 25, page 57, 1983), many new cephalosporins have become available in the USA.
Issue 823 · July 27, 1990
Trimethoprim-Polymyxin B for Bacterial Conjunctivitis

Bacterial infections of the conjunctivae are usually self-limited, but topical antimicrobial therapy can be helpful. A solution of trimethoprim sulfate 0.1% with polymyxin B sulfate 10,000 units/ml ( Polytrim…

Med Lett Drugs Ther. 1990 Jul 27; 32(823):71-2
Bacterial infections of the conjunctivae are usually self-limited, but topical antimicrobial therapy can be helpful. A solution of trimethoprim sulfate 0.1% with polymyxin B sulfate 10,000 units/ml ( Polytrim - Burroughs Wellcome, distributed by Allergan) was recently marketed in the USA for treatment of superficial ocular bacterial infections.
Issue 822 · July 13, 1990
Cefmetazole Sodium (Zefazone)

Cefmetazole sodium ( Zefazone - Upjohn), a second-generation parenteral cephalosporin, was recently marketed in the USA for intravenous (IV) treatment of various infections caused by susceptible organisms.…

Med Lett Drugs Ther. 1990 Jul 13; 32(822):65-6
Cefmetazole sodium ( Zefazone - Upjohn), a second-generation parenteral cephalosporin, was recently marketed in the USA for intravenous (IV) treatment of various infections caused by susceptible organisms. Like cefotetan ( Cefotan ), cefamandole ( Mandol ), cefoperazone ( Cefobid ), and moxalactam ( Moxam ), cefmetazole contains a methylthiotetrazole group that has been associated with prothrombin deficiency.
Issue 817 · May 4, 1990
The Choice of Antimicrobial Drugs
Med Lett Drugs Ther. 1990 May 4; 32(817):41-8
Issue 803 · October 20, 1989
Treatment of Clostridium Difficile Diarrhea

The gram-positive bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea and pseudomembranous colitis (R Fekety in GL Mandell et al, eds, Principles and Practice…

Med Lett Drugs Ther. 1989 Oct 20; 31(803):94-5
The gram-positive bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea and pseudomembranous colitis (R Fekety in GL Mandell et al, eds, Principles and Practice of Infectious Diseases , 3rd ed, New York:Churchill Livingstone, 1990, page 863). C. difficile colitis usually develops during or soon after antibiotic treatment. Virtually any antimicrobial agent can cause the disorder, but clindamycin, ampicillin and the cephalosporins have been implicated most frequently. Pseudomembranous colitis was recently reported in five patients who had each taken only a single dose of a cephalosporin (JP Freiman et al, JAMA, 262:902, August 18, 1989).
Issue 798 · August 11, 1989
Cefixime - A New Oral Cephalosporin

Cefixime ( Suprax - Lederle), an oral cephalosporin antibiotic, was recently approved for marketing by the US Food and Drug Administration. Claimed to be the first oral third-generation cephalosporin, the new…

Med Lett Drugs Ther. 1989 Aug 11; 31(798):73-5
Cefixime ( Suprax - Lederle), an oral cephalosporin antibiotic, was recently approved for marketing by the US Food and Drug Administration. Claimed to be the first oral third-generation cephalosporin, the new drug is offered for once-a-day treatment of otitis media, pharyngitis, bronchitis and urinary tract infections.
Issue 798 · August 11, 1989
Topical Metronidazole For Rosacea

A topical formulation of 0.75% metronidazole gel ( MetroGel - Curatek), an antibacterial, antiparasitic agent, was recently approved by the US Food and Drug Administration for treatment of rosacea.

Med Lett Drugs Ther. 1989 Aug 11; 31(798):75-6
A topical formulation of 0.75% metronidazole gel ( MetroGel - Curatek), an antibacterial, antiparasitic agent, was recently approved by the US Food and Drug Administration for treatment of rosacea.
Issue 794 · June 16, 1989
Treatment of Lyme Disease

Lyme disease, a multisystem bacterial transmitted by Ixodid ticks, particularly in early summer, continues to be a common problem in the USA and many other countries. Since last year (Medical Letter, 30:65,…

Med Lett Drugs Ther. 1989 Jun 16; 31(794):57-9
Lyme disease, a multisystem bacterial transmitted by Ixodid ticks, particularly in early summer, continues to be a common problem in the USA and many other countries. Since last year (Medical Letter, 30:65, 1988), some new information has become available, but data on the choice, dosage and duration of antibiotic therapy are still available, but data on the choice, dosage and duration of antibiotic therapy are still limited.
Issue 776 · October 7, 1988
Prevention of Pneumocystis Carinii Pneumonia

Pneumocystis carinii pneumonia (PCP) is a common cause of death in patients with acquired immune deficiency syndrome (AIDS). PCP is the first serious opportunistic infection in more than 60% of patients with…

Med Lett Drugs Ther. 1988 Oct 7; 30(776):94-5
Pneumocystis carinii pneumonia (PCP) is a common cause of death in patients with acquired immune deficiency syndrome (AIDS). PCP is the first serious opportunistic infection in more than 60% of patients with AIDS, and about 80% of AIDS patients develop PCP at least once (AE Glatt et al, N Engl J Med, 318:1439, June 2, 1988). Many studies using drugs to prevent PCP in patients with AIDS have recently been reported.
Issue 772 · August 12, 1988
Penicillin Allergy

A penicillin is the drug of choice for treatment of many infections, but allergic reactions to these drugs occur frequently and, rarely, can be fatal. From 5% to 20% of patients have a history of a rash or…

Med Lett Drugs Ther. 1988 Aug 12; 30(772):79-80
A penicillin is the drug of choice for treatment of many infections, but allergic reactions to these drugs occur frequently and, rarely, can be fatal. From 5% to 20% of patients have a history of a rash or some other reaction while taking a penicillin, but maculopapular rashes with ampicillin or amoxicillin, especially in children with infectious mononucleosis, are probably not allergic.
Issue 769 · July 1, 1988
Treatment Lyme Disease

Lyme Disease, a multisystem inflammatory disorder transmitted by lxodid ticks and caused by the spirochete Borrelia burgdorferi , is now the most common tick-transmitted illness in the USA. It has been…

Med Lett Drugs Ther. 1988 Jul 1; 30(769):65-6
Lyme Disease, a multisystem inflammatory disorder transmitted by lxodid ticks and caused by the spirochete Borrelia burgdorferi , is now the most common tick-transmitted illness in the USA. It has been reported in 32 states and on all other continents except Antarctica. Infected ticks have been found not only in wooded areas, but also on well-maintained suburban lawns (RC Falco and D Fish, Am J Epidemiol, 127:826, April 1988). Optimal treatment for this newly discovered disease is still being determined, but some recommendations based on published experience and work in progress can be made.
Issue 767 · June 3, 1988
Cefuroxime Axetil

Cefuroxime axetil ( Ceftin - Glaxo), an oral form of the second-generation parenteral cephalosporin cefuroxime ( Zinacef ), was recently marketed in the USA. Previously available oral cephalosporins are the…

Med Lett Drugs Ther. 1988 Jun 3; 30(767):57-9
Cefuroxime axetil ( Ceftin - Glaxo), an oral form of the second-generation parenteral cephalosporin cefuroxime ( Zinacef ), was recently marketed in the USA. Previously available oral cephalosporins are the first-generation drugs cephalexin ( Keflex ; and others), cephradine ( Anspor ; and others) and cefadroxil ( Duricef ; and others), and the second-generation cefaclor ( Ceclor ); second-generation cephalosporins have more activity against gram-negative bacteria.
Issue 766 · May 20, 1988
Mupirocin - A New Topical Antibiotic

Mupirocin ( Bactroban - Beecham), a topical antibiotic formerly called pseudomonic acid, was recently approved by the US Food and Drug Administration for treatment of impetigo. It will be sold as a 2% ointment…

Med Lett Drugs Ther. 1988 May 20; 30(766):55-6
Mupirocin ( Bactroban - Beecham), a topical antibiotic formerly called pseudomonic acid, was recently approved by the US Food and Drug Administration for treatment of impetigo. It will be sold as a 2% ointment available only by prescription.
Issue 763 · April 8, 1988
Drugs for Tuberculosis

After many years of decline, the incidence of tuberculosis has recently increased because the disease occurs in patients with AIDS (Morbid Mortal Weekly Rep, 36:817, Jan 1, 1988). For uncomplicated…

Med Lett Drugs Ther. 1988 Apr 8; 30(763):43-4
After many years of decline, the incidence of tuberculosis has recently increased because the disease occurs in patients with AIDS (Morbid Mortal Weekly Rep, 36:817, Jan 1, 1988). For uncomplicated tuberculosis, the recent trend in tuberculosis treatment has been toward a shorter period of therapy and increased use of pyrazinamide.
Issue 762 · March 25, 1988
The Choice Of Antimicrobial Drugs

Since The Medical Letter last reviewed the choice of antimicrobial drugs, some new drugs have become available, and some new clinical studies of older drugs have been published. The drug of choice for…

Med Lett Drugs Ther. 1988 Mar 25; 30(762):33-40
Since The Medical Letter last reviewed the choice of antimicrobial drugs, some new drugs have become available, and some new clinical studies of older drugs have been published. The drug of choice for treatment of an infection is usually the most active drug against the pathogenic organism or the least toxic alternative among several effective agents. Sometimes the choice of drugs is modified by the site of infection; one drug may penetrate better than another into bile, urine, or cerebrospinal fluid. The patient's clinical status may also influence the choice as, for example, when a patient has diminished renal or hepatic function, is allergic to penicillin is immunocompromised, or is pregnant. Finally, when other factors are about equal, the relative cost may be a consideration.
Issue 758 · January 29, 1988
Ciprofloxacin

Ciprofloxacin hydrochloride ( Cipro - Miles), a synthetic antibacterial agent, was recently marketed in the USA for oral treatment of a wide variety of infections. Ciprofloxacin is the second fluoroquinolone…

Med Lett Drugs Ther. 1988 Jan 29; 30(758):11-3
Ciprofloxacin hydrochloride ( Cipro - Miles), a synthetic antibacterial agent, was recently marketed in the USA for oral treatment of a wide variety of infections. Ciprofloxacin is the second fluoroquinolone to become available in this country; norfloxacin ( Noroxin - Medical Letter, 29:25, 1987) is marketed only for treatment of urinary tract infections. Fluoroquinolones are more potent and have a much broader spectrum of activity than older quinolones such as nalidixic acid ( NegGram ).